Suppr超能文献

内脏利什曼病在埃塞俄比亚北部的治疗结果及相关因素。

Visceral Leishmaniasis Treatment Outcome and Associated Factors in Northern Ethiopia.

机构信息

Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.

出版信息

Biomed Res Int. 2019 Aug 21;2019:3513957. doi: 10.1155/2019/3513957. eCollection 2019.

Abstract

BACKGROUND

Visceral leishmaniasis (VL), one of the most neglected tropical diseases, is placing a huge burden on Ethiopia. Despite the introduction of antileishmanial drugs, treatment outcomes across regions are variable due to drug resistance and other factors. Thus, understanding of VL treatment outcomes and its contributing factors helps decisions on treatment. However, the magnitude and the risk factors of poor treatment outcome are not well studied in our setting. Therefore, our study was designed to assess treatment outcomes and associated factors in patients with VL.

MATERIALS AND METHODS

A cross-sectional study was conducted in VL patients admitted between June 2016 and April 2018 to Ayder Comprehensive Specialized Hospital, Tigray, Northern Ethiopia. Data was collected through chart review of patient records. Logistic regression analysis was used to identify factors associated with poor treatment outcome.

RESULTS

A total of 148 VL patients were included in the study. The mean age (SD) of the patients was 32.86 (11.9) years; most of them (94.6%) were male patients. The proportion of poor treatment outcome was 12.1%. Multivariable logistic regression analysis showed that long duration of illness (> four weeks) (adjusted odds ratio (AOR): 6.1 [95% confidence interval (CI); 1.3-28.6], p=0.02) and concomitant tuberculosis (TB) infection (AOR 4.6 [95% CI; 1.1-19.1], p=0.04) were the independent predictors of poor treatment outcome.

CONCLUSIONS

Poor treatment outcome was observed in a considerable proportion of VL patients. Long duration of illness and coinfection with TB were associated with poor VL treatment outcome. Hence, early diagnosis and effective prompt treatment are important to improve treatment outcomes among VL patients. Special attention should also be given in the treatment of VL/TB coinfected patients in our setting.

摘要

背景

内脏利什曼病(VL)是最被忽视的热带病之一,给埃塞俄比亚带来了巨大的负担。尽管已经引入了抗利什曼原虫药物,但由于耐药性和其他因素,不同地区的治疗结果存在差异。因此,了解 VL 的治疗结果及其影响因素有助于做出治疗决策。然而,在我们的研究环境中,VL 治疗结果不佳的程度和相关因素尚未得到充分研究。因此,我们的研究旨在评估 VL 患者的治疗结果及其相关因素。

材料和方法

本横断面研究于 2016 年 6 月至 2018 年 4 月在埃塞俄比亚提格雷州阿德尔综合专科医院住院的 VL 患者中进行。通过查阅患者病历收集数据。采用逻辑回归分析确定与不良治疗结果相关的因素。

结果

本研究共纳入 148 例 VL 患者。患者的平均年龄(标准差)为 32.86(11.9)岁;大多数(94.6%)为男性患者。不良治疗结果的比例为 12.1%。多变量逻辑回归分析表明,疾病持续时间长(>4 周)(调整后的优势比(AOR):6.1[95%置信区间(CI);1.3-28.6],p=0.02)和合并结核病(TB)感染(AOR 4.6[95%CI;1.1-19.1],p=0.04)是不良治疗结果的独立预测因素。

结论

相当一部分 VL 患者的治疗结果不佳。疾病持续时间长和合并 TB 感染与 VL 治疗结果不佳相关。因此,早期诊断和及时有效的治疗对于提高 VL 患者的治疗结果非常重要。在我们的研究环境中,还应特别关注 VL/TB 合并感染患者的治疗。

相似文献

引用本文的文献

7
PF-429242, a Subtilisin Inhibitor, Is Effective Against .PF-429242,一种枯草杆菌蛋白酶抑制剂,对……有效。
Front Microbiol. 2021 Jan 28;12:583834. doi: 10.3389/fmicb.2021.583834. eCollection 2021.

本文引用的文献

6
Chemotherapy of leishmaniasis: present challenges.利什曼病的化疗:当前面临的挑战
Parasitology. 2018 Apr;145(4):464-480. doi: 10.1017/S0031182016002523. Epub 2017 Jan 20.
9
Pediatric visceral leishmaniasis in northwest of Iran.伊朗西北部的小儿内脏利什曼病
Medicine (Baltimore). 2016 Nov;95(44):e5261. doi: 10.1097/MD.0000000000005261.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验